Medanta Q2 FY27 Revenue Jumps 33.6% to ₹14,690 Million on Strong Volume Growth
Medanta reported Q2 FY27 revenue of ₹14,690 million, a 33.6% y-o-y increase, driven by 34% volume growth. Operating EBITDA rose 60.2% to ₹3,701 million with improved margins. PAT increased 38.3% to ₹2,191 million. The company plans significant capex of ~₹62,390 million over 4-5 years for expansion.
The substantial revenue and profit growth, coupled with strategic capacity expansions and a significant future capex plan, indicate a strong positive impact on the company's growth trajectory and market position.
The company reported strong year-on-year growth in revenue, operating EBITDA, and PAT, along with improved margins and significant capacity expansion. The achievement of EBITDA breakeven at the Noida facility and robust growth in ancillary businesses further contribute to the positive sentiment.
Global Health Limited (Medanta) announced robust financial results for the second quarter and first half of FY2027. In Q2 FY27, the company reported a significant 33.6% year-on-year (y-o-y) increase in revenue from operations, reaching ₹14,690 million. This growth was primarily driven by a 34% surge in patient volumes.
Operating EBITDA saw an impressive 60.2% y-o-y growth to ₹3,701 million, with margins expanding to 25.2% from 21.0% in Q2 FY26. Profit After Tax (PAT) grew by 38.3% y-o-y to ₹2,191 million, with PAT margins improving to 14.9% from 14.4%.
The company added 74 new beds across its network during the quarter, with 25 beds at Lucknow and 49 at Noida, increasing its total census bed capacity to 3,115. Occupancy rates improved to approximately 67% on the expanded bed capacity. Average Revenue Per Patient (ARPP) was ₹2.06 lakh, a slight increase from ₹2.01 lakh in the prior year quarter.
Cluster 2 hospitals (Lucknow, Patna, and Noida) showed exceptional growth with revenue up 63.2% y-o-y and Operating EBITDA up 110.0% y-o-y. The Noida hospital achieved EBITDA breakeven in Q2 FY27. The company also reported strong growth in its OPD Pharmacy and Labs business, with revenues increasing by 52.9% and 29.0% respectively.
Looking ahead, Medanta has outlined a significant capex plan of approximately ₹62,390 million over the next 4-5 years for expansion projects across multiple cities, including Mumbai, Delhi, Guwahati, Varanasi, and Ghaziabad.
What to do with a filing like this
Global Health Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Global Health Limited. Read the original for the full detail.